08:06 AM EDT, 10/07/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that a phase 3b study of its inhaled anti-inflammatory rescue medication Airsupra met its primary endpoint of statistically significant and clinically meaningful reduction in the risk of severe exacerbation compared with albuterol in patients with intermittent or mild persistent asthma.

The company said no new safety concerns were observed and data from the trial will be shared with authorities.

Airsupra, which combines albuterol and budesonide, is approved in the US to be used as needed as a rescue inhaler in people aged 18 years and older to treat or prevent symptoms of asthma and help prevent sudden severe breathing problems, the company said.

Price: 77.09, Change: -0.38, Percent Change: -0.49